Novartis (VTX:NOVN) received a CHF 95 target price from equities research analysts at Societe Generale in a report issued on Wednesday. The brokerage presently has a “buy” rating on the stock. Societe Generale’s price objective would suggest a potential upside of 22.05% from the company’s current price.
A number of other research analysts have also weighed in on NOVN. Bank of America set a CHF 87 target price on Novartis and gave the company a “sell” rating in a report on Wednesday, December 6th. JPMorgan Chase & Co. set a CHF 84 target price on Novartis and gave the company a “neutral” rating in a report on Friday, December 29th. Morgan Stanley set a CHF 92 target price on Novartis and gave the company a “buy” rating in a report on Friday, December 1st. Deutsche Bank set a CHF 90 target price on Novartis and gave the company a “neutral” rating in a report on Monday, January 15th. Finally, Barclays set a CHF 80 target price on Novartis and gave the company a “sell” rating in a report on Tuesday, February 20th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and seven have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of CHF 88.88.
Shares of Novartis (VTX:NOVN) traded up CHF 0.14 during trading on Wednesday, reaching CHF 77.84. The company’s stock had a trading volume of 8,200,000 shares, compared to its average volume of 5,960,000. Novartis has a 12-month low of CHF 72.45 and a 12-month high of CHF 88.30. The firm has a market capitalization of $202,920.00 and a PE ratio of 25.19.
Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.